Cantharidin
Brand Names: Ycanth
Methodology & AI Transparency ⓘ
Cantharidin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage ycanth: is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
- 2 Real-world patient consensus: Tracked across 7 patient dosage logs with a 86% satisfaction benchmark (RxCUI 244521).
- 3 Typical cash cost range: Dispensing cost comparison spans $36.04 mail/discount cash up to $88.30 uninsured retail (federal NADAC $0.6800).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Cantharidin: pruritus (4.2%), peripheral edema (3.9%), application-site irritation (6.7%).
Ask our AI Specialists anything about Cantharidin
Cantharidin Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage ycanth: is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 )
12.1 Mechanism of Action The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown. Cantharidin operates pharmacologically within the FDA Prescription Therapeutic Agent class (RxNorm 244521; NDC 71349-070, 71349-999), engaging target pathways across 3.2 mg/.45mL Solution; Individualized Cantharidin continuation schedule per specialist review dosing.
Pharmacokinetic profiling of Cantharidin demonstrates an elimination half-life of Approximately 6–13 hours terminal plasma half-life for Cantharidin with Estimated 50%–62% oral systemic absorption for Cantharidin systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of cantharidin coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–2 hours post-dose for cantharidin.
Titration schedules for Cantharidin (3.2 mg/.45mL Solution → Individualized Cantharidin continuation schedule per specialist review) require excluding documented intolerance or hypersensitivity reaction involving cantharidin (fda prescription therapeutic agent); concurrent restricted medications flagged in section 4/7 of the cantharidin dailymed monograph (244521); real-world patient logs highlight nausea (9% of reports), headache (7.3% of reports), application-site irritation (6.7% of reports) alongside a 86.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Cantharidin (fda prescription therapeutic agent).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Cantharidin dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Cantharidin (fda prescription therapeutic agent)
- Concurrent restricted medications flagged in Section 4/7 of the Cantharidin DailyMed monograph (244521)
Logged Side-Effect Incidence (7 Reports)
Cantharidin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cantharidin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on YCANTH TM (Cantharidin) skin-applied Common side effects were mild to moderate, such as lesions at the site of application, severe itching, and pain. Skinmed • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37945366 ↗ |
| Can This Approach Help? Inside the Latest Research on Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Pooled analyses showed a significantly higher percentage of participants with complete molluscum lesion clearance and larger reductions in lesion counts with VP-102 than with vehicle. American journal of clinical dermatology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33599960 ↗ |
Cantharidin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6800/unit (~$20.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $88.30 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $36.04 / mo | View logs ↓ |
Cantharidin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cantharidin RxNorm Concept ID | 244521 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $88.30 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $36.04 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cantharidin Patient Community, Cohort Filters & Dosage Logs
Cross-verified Cantharidin (fda prescription therapeutic agent) monograph synthesizing RxNorm 244521, openFDA FAERS signals, and $36.04–$88.30 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cantharidin community threads and patient logs by age, biological sex, dosage, and treatment duration.